Zacks Rating on Seattle Genetics (SGEN)

Seattle Genetics (SGEN) : 10 analysts are covering Seattle Genetics (SGEN) and their average rating on the stock is 2.1, which is read as a Buy. 4 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. Seattle Genetics (SGEN) also receives 1 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 5 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Seattle Genetics (SGEN) : 9 Wall Street analysts covering Seattle Genetics (SGEN) believe that the average level the stock could reach for the short term is $56.78. The maximum price target given is $130 and the minimum target for short term is around $37, hence the standard deviation is calculated at $28.84.


Shares of Seattle Genetics, Inc. rose by 4.41% in the last five trading days and 7.42% for the last 4 weeks. Seattle Genetics, Inc. is up 19.56% in the last 3-month period. Year-to-Date the stock performance stands at 6.48%. Seattle Genetics (NASDAQ:SGEN): stock turned positive on Tuesday. Though the stock opened at $47.31, the bulls momentum made the stock top out at $48.66 level for the day. The stock recorded a low of $47.14 and closed the trading day at $47.79, in the green by 1.55%. The total traded volume for the day was 782,511. The stock had closed at $47.06 in the previous days trading.

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Companys marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing its technology. In addition to ADCETRIS, the Companys pipeline includes six clinical-stage ADC programs consisting of SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. In addition, it has multiple preclinical and research-stage programs that employ its technologies. Its technologies include ADC technology and Seattle Genetics sugar-engineered antibody (SEA) technology.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.